Corvidane is developing Corvida™ to treat TWO formidable diseases.
Corvidane uses a novel approach to treat metabolic and inflammatory diseases.
Corvida(TM) for Atherosclerosis - In development to be a Best-in-Class, orally administered adjunct to lipid regulating therapies (Statins/PCSK9) that targets atherosclerotic plaques, the major factor in Heart Attacks and Stroke.
Corvida(TM) for MASH - In development to be a Best-in-Class, orally administered drug to treat MASH, which is the leading cause of liver transplants in the United States.
Company Details
- Employees
- 3
- Founded
- 2014
- Address
- Stationsplein 45, 4th Floor,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- bbncardio.com
- Keywords
- IT Consulting.
- HQ
- Netherlands &, New York
Corvidane Questions
Corvidane's website is bbncardio.com
Corvidane's LinkedIn profile is https://www.linkedin.com/company/burke&boyer
Corvidane has
3 employees.
View email and phone details for 3
employees at Corvidane.
Corvidane's industry is
Pharmaceutical Manufacturing
Corvidane's categories are Pharmaceutical Manufacturing
Corvidane's founding year is 2014
